Researchers found that patients diagnosed with HCC during 2013-2019 were less likely to die from HCC or from any cause than patients who were diagnosed during 2006-2012.
It may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit from immunotherapy, according to a preclinical study.
In this GEN webinar, Jeremy Tomlinson, PhD, will discuss the pathogenesis of MASLD, share examples from recent research that ...